Defendant

Impax Laboratories, Inc.

1 case as defendant.

Cases
1
Active
0
1 closed
Filed
—
Top venue
S.D. Indiana
1 case

Company profile

Impax Laboratories, Inc. is a U.S. specialty pharmaceutical company headquartered in Hayward, California (30831 Huntwood Avenue). Its predecessor, privately held Impax Pharmaceuticals, Inc., was founded in 1995 by Charles Hsiao and Larry Hsu; the current entity was formed on December 14, 1999, when publicly traded Global Pharmaceutical Corporation and Impax Pharmaceuticals completed a reverse merger. Impax traded on NASDAQ under the ticker IPXL and reported roughly $824 million in total revenue for FY2016 (down from about $840 million in 2015), with a market capitalization of about $1.48 billion at the time of its 2017 merger announcement. On May 4, 2018, Impax completed an all-stock business combination with Amneal Pharmaceuticals LLC; Impax shareholders received approximately 25% of the combined company, which is named Amneal Pharmaceuticals, Inc. and trades on NASDAQ (AMRX). Impax shares ceased trading on NASDAQ on that date. As part of the transaction, Impax became Impax Laboratories, LLC.

Operations. Impax developed, manufactured, and marketed both generic and branded pharmaceuticals, organized into two divisions. Impax Generics (incorporating the legacy Global Pharmaceuticals business plus acquired CorePharma and Lineage Therapeutics operations) developed and sold controlled-release and other "technically challenging" generic products across a broad range of therapeutic areas. Impax Specialty Pharma marketed proprietary branded products, principally for central nervous system disorders and other select specialty segments. The company had additional facilities in New Jersey, Pennsylvania, and Taiwan, and pursued partnership arrangements for alternative dosage forms such as injectables, nasal sprays, inhalers, patches, and creams.

Litigation posture. Impax was an operating company, not a patent assertion entity. In the tracked data it appears in one case, solely as a defendant; it filed no plaintiff-side suits. This is consistent with the standard Hatch-Waxman dynamic, in which brand manufacturers sue generic filers following Paragraph IV certifications.

Notable case. Eli Lilly and Company v. Impax Laboratories, Inc. (No. 1:08-cv-01549, U.S. District Court for the Southern District of Indiana, filed November 2008) alleged infringement of U.S. Patent No. 5,023,269 based on Impax's ANDA for duloxetine hydrochloride delayed-release capsules, generic to Cymbalta. Lilly filed parallel suits against several other generic filers; the cases were consolidated, with most defendants staying their cases under stipulations to be bound by the outcome.